We will be contrasting the differences between Proteostasis Therapeutics Inc. (NASDAQ:PTI) and Abeona Therapeutics Inc. (NASDAQ:ABEO) as far as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Table 1 shows the gross revenue, earnings per share and valuation for Proteostasis Therapeutics Inc. and Abeona Therapeutics Inc.

Profitability

Table 2 provides us Proteostasis Therapeutics Inc. and Abeona Therapeutics Inc.s return on equity, return on assets and net margins.

Volatility and Risk

Proteostasis Therapeutics Inc.s volatility measures that its 171.00% less volatile than Standard and Poors 500 due to its -0.71 beta. From a competition point of view, Abeona Therapeutics Inc. has a 1.84 beta which is 84.00% more volatile compared to Standard and Poors 500.

Liquidity

The Current Ratio and Quick Ratio of Proteostasis Therapeutics Inc. are 11.3 and 11.3 respectively. Its competitor Abeona Therapeutics Inc.s Current Ratio is 3.3 and its Quick Ratio is 3.3. Proteostasis Therapeutics Inc. can pay off short and long-term obligations better than Abeona Therapeutics Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Proteostasis Therapeutics Inc. and Abeona Therapeutics Inc.

Abeona Therapeutics Inc. on the other hand boasts of a $12.33 consensus target price and a 387.35% potential upside.

Institutional & Insider Ownership

Roughly 60.5% of Proteostasis Therapeutics Inc. shares are owned by institutional investors while 64.4% of Abeona Therapeutics Inc. are owned by institutional investors. Insiders owned roughly 0.3% of Proteostasis Therapeutics Inc.s shares. Competitively, 0.3% are Abeona Therapeutics Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Proteostasis Therapeutics Inc.s stock price has bigger decline than Abeona Therapeutics Inc.

Summary

Abeona Therapeutics Inc. beats on 6 of the 10 factors Proteostasis Therapeutics Inc.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

The rest is here:
Reviewing Proteostasis Therapeutics Inc. (PTI)'s and Abeona Therapeutics Inc. (NASDAQ:ABEO)'s results - MS Wkly

Comments are closed.